Defining the role of developmental context in oncohistone-driven gliomagenesis

定义发育背景在肿瘤组蛋白驱动的神经胶质瘤发生中的作用

基本信息

  • 批准号:
    10507387
  • 负责人:
  • 金额:
    $ 19.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-15 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

Project Summary The overarching goal of this proposal is to define the interplay of epigenetics and developmental context in driving pediatric high-grade gliomas (pHGG), universally lethal tumors defined by histone mutations, so as to identify better targeted treatments. This work utilizes an innovative cerebral organoid-based model that allows side-by-side comparison of oncohistone mutants and dynamic modulation of oncogene expression in a three- dimensional human context. Leveraging this innovative model, Dr. Graham will use cutting-edge single cell profiling techniques and preclinical glioma modeling to address unanswered questions that currently hamper therapeutic development for these patients. In Aim 1, chromatin profiling and single cell RNA sequencing will be used to investigate the distinct effects of two different oncohistones (H3.3K27M and H3.3G34V) during neural development. In Aim 2, the timing and order of mutations will be manipulated to evaluate the impact of cellular and mutational context on tumor phenotype. Finally, in Aim 3, orthogonal genetic “rescue” and pharmacologic inhibition approaches will be used to interrogate the role of these mutations in tumor maintenance. This work, as well as Dr. Graham's career goal, is well-aligned with the NINDS mission to seek basic knowledge about the brain and to translate that knowledge into clinical impact. Through the proposed studies and the accompanying career development plan, Dr. Graham will gain essential training in epigenetics, bioinformatics and preclinical glioma studies, critical gaps in her current skillset. Dr. Graham is an Instructor of Neuro-Oncology under the mentorship of Dr. Ingo Mellinghoff at Memorial Sloan Kettering Cancer Center (MSK). Dr. Mellinghoff is a leader in translational glioma research with a strong track record of mentoring trainees to independence. He and Dr. Graham have assembled an exceptional Advisory Committee with expertise in chromatin biology, translational oncology, and bioinformatic analyses: Dr. Kristian Helin, Dr. Ross Levine and Dr. Nicholas Socci. MSK provides an outstanding environment for cultivating budding careers in biomedical research, with unparalleled resources, support, and opportunities for collaboration. Upon completion of the proposed work, Dr. Graham will be ideally positioned and uniquely qualified for a career as an independent investigator elucidating fundamental aspects of epigenetic regulation in neural lineage commitment and applying her findings to address the unmet needs in the treatment of malignant glioma.
项目摘要 该提案的总体目标是确定表观遗传学和发育背景的相互作用, 驱动儿科高级别胶质瘤(pHGG),普遍致命的肿瘤定义的组蛋白突变,以便 更好的针对性治疗。这项工作利用了一种创新的基于脑类器官的模型, 并排比较癌组蛋白突变体和癌基因表达的动态调节, 多维人文背景利用这种创新模式,Graham博士将使用尖端的单细胞 分析技术和临床前胶质瘤建模,以解决目前阻碍 为这些患者提供治疗。在目标1中,染色质分析和单细胞RNA测序将 研究两种不同的癌组蛋白(H3.3K27M和H3.3G34V)在神经细胞凋亡过程中的不同作用。 发展在目标2中,将操纵突变的时间和顺序,以评估细胞免疫的影响。 和肿瘤表型的突变背景。最后,在目标3中,正交遗传“拯救”和药理学 将使用抑制方法来研究这些突变在肿瘤维持中的作用。 这项工作,以及格雷厄姆博士的职业目标,是与NINDS的使命,以寻求基本的 关于大脑的知识,并将这些知识转化为临床影响。通过拟议的研究 以及随之而来的职业发展计划,格雷厄姆博士将获得表观遗传学的基本培训, 生物信息学和临床前胶质瘤研究,她目前的技能的关键差距。格雷厄姆博士是一名教师, 在纪念斯隆凯特琳癌症中心Ingo Mellinghoff博士的指导下,神经肿瘤学 (MSK)。Mellinghoff博士是转化胶质瘤研究的领导者, 实习生独立他和格雷厄姆博士组建了一个特殊的咨询委员会, 染色质生物学、转化肿瘤学和生物信息学分析方面的专业知识:Kristian Helin博士、Ross博士 莱文和尼古拉斯·索奇博士。MSK提供了一个优秀的环境,培养萌芽的职业生涯, 生物医学研究,拥有无与伦比的资源,支持和合作机会。后 完成拟议的工作,格雷厄姆博士将是理想的定位和独特的职业资格, 一个独立的研究者阐明神经谱系中表观遗传调控的基本方面 承诺和应用她的研究结果,以解决在恶性胶质瘤的治疗未得到满足的需求。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maya Srikanth Graham其他文献

Maya Srikanth Graham的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maya Srikanth Graham', 18)}}的其他基金

Defining the Role of Developmental Context in Oncohistone-Driven Gliomagenesis
定义发育背景在肿瘤组蛋白驱动的胶质瘤发生中的作用
  • 批准号:
    10675589
  • 财政年份:
    2022
  • 资助金额:
    $ 19.57万
  • 项目类别:
Inhibition of Brain Tumor Stem Cell Tumorigenicity using Self-assembling Nanogels
使用自组装纳米凝胶抑制脑肿瘤干细胞致瘤性
  • 批准号:
    7675089
  • 财政年份:
    2009
  • 资助金额:
    $ 19.57万
  • 项目类别:
Inhibition of Brain Tumor Stem Cell Tumorigenicity using Self-assembling Nanogels
使用自组装纳米凝胶抑制脑肿瘤干细胞致瘤性
  • 批准号:
    8259203
  • 财政年份:
    2009
  • 资助金额:
    $ 19.57万
  • 项目类别:
Inhibition of Brain Tumor Stem Cell Tumorigenicity using Self-assembling Nanogels
使用自组装纳米凝胶抑制脑肿瘤干细胞致瘤性
  • 批准号:
    8064370
  • 财政年份:
    2009
  • 资助金额:
    $ 19.57万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.57万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了